Kohjin Bio Co.,Ltd. (177A) AI Stock Analysis

• Market Cap: ¥7.28B
• Dividend Yield: 1.62%
• Average Volume (3M): 3.64K
• Price to Earnings (P/E): 10.1
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 23.43
• Shares Outstanding: 5,111,600
• 10 Day Avg. Volume: 4,170
• 30 Day Avg. Volume: 3,643
• PEG Ratio: 0.16
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 318.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 20,916.77
• Revenue Forecast (FY): ¥802.57B

• Rating: 67 Neutral
• Price Target: ¥1,660.00 ▲(8.85% Upside)

Kohjin Bio Co., Ltd. shows strong financial performance with robust growth in revenue and profitability, supported by a stable balance sheet. However, the technical indicators suggest a bearish trend, which could pose short-term risks. The valuation is reasonable, with a moderate P/E ratio and dividend yield, making it attractive for long-term investors. The absence of recent earnings call insights or notable corporate events limits additional context.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and competitiveness.

Profitability

High and improving profit margins reflect efficient cost management and pricing power, enhancing the company's ability to reinvest in growth.

Balance Sheet Health

A strong equity ratio indicates financial stability and lower risk, providing a solid foundation for future investments and growth opportunities.

Negative Factors

Free Cash Flow

Limited free cash flow generation can restrict the company's ability to fund new projects or return capital to shareholders, impacting long-term flexibility.

Operational Fluctuations

Operational fluctuations can lead to unpredictable earnings, affecting investor confidence and potentially hindering strategic planning.

Debt Vigilance

While current debt levels are manageable, ongoing vigilance is necessary to prevent financial strain, ensuring long-term operational stability.

Kohjin Bio Co.,Ltd. Business Overview & Revenue Model

Company Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development and production of bioactive compounds and fermentation products. The company operates primarily in the health and wellness sectors, focusing on nutritional supplements, functional foods, and pharmaceutical intermediates. Kohjin Bio is known for its innovative approaches to biotechnology, leveraging fermentation technology to create high-quality, bioavailable ingredients that cater to a growing market for health-conscious consumers.

How the Company Makes Money

Kohjin Bio generates revenue through multiple key streams, including the sale of proprietary bioactive ingredients and fermentation products to manufacturers in the dietary supplement and functional food sectors. The company engages in business-to-business transactions, supplying its products to other companies that incorporate these ingredients into their own offerings. Additionally, Kohjin Bio may generate income through research and development partnerships with larger pharmaceutical or nutraceutical companies, providing expertise and technology in exchange for funding or royalties. The company's commitment to innovation and high-quality production processes allows it to maintain competitive pricing and establish long-term relationships with clients, contributing significantly to its earnings.

Kohjin Bio Co.,Ltd. Financial Statement Overview

Summary

Kohjin Bio Co., Ltd. demonstrates robust financial health with strong growth in revenue and profitability, supported by a stable balance sheet. Effective leverage management and profitability metrics point to a solid operational footing. While cash flow generation is improving, enhancing free cash flow remains a focus area to bolster financial resilience further.

Income Statement

Kohjin Bio Co., Ltd. shows a strong revenue growth rate of 9.14% from 2024 to 2025 and a notable increase in net income, indicating positive momentum. The gross profit margin stands at 45.44%, and the net profit margin improved to 15.26%, reflecting efficient cost management. EBIT and EBITDA margins are also healthy, at 19.04% and 27.01%, respectively, suggesting robust profitability. However, the volatility in EBIT over the years indicates some operational fluctuations.

Balance Sheet

The company's balance sheet reflects stability with a solid equity ratio of 63.78%, indicating a strong capitalization. The debt-to-equity ratio has improved to 0.41, which suggests effective leverage management. Return on Equity (ROE) is impressive at 13.75%, demonstrating efficient use of shareholder funds. Despite these strengths, the company needs to maintain vigilance over its debt levels to ensure sustained financial stability.

Cash Flow

Operating cash flow is strong, with a good ratio of operating cash flow to net income at 1.15, indicating efficient cash conversion. Free cash flow to net income ratio is 0.04, showing modest free cash flow generation. However, the free cash flow growth rate of 7.52% indicates improvement, though further enhancements in cash generation would strengthen financial flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	5.18B	5.21B	4.77B	4.74B	3.95B
Gross Profit	2.31B	2.37B	1.88B	2.45B	2.04B
EBITDA	1.26B	1.41B	958.10M	1.44B	1.14B
Net Income	714.00M	794.76M	384.00M	829.79M	587.67M
Balance Sheet
Total Assets	9.17B	9.07B	6.59B	6.13B	5.60B
Cash, Cash Equivalents and Short-Term Investments	3.10B	3.15B	1.73B	1.46B	1.73B
Total Debt	1.99B	2.39B	2.47B	2.10B	2.23B
Total Liabilities	3.46B	3.28B	3.25B	3.12B	3.38B
Stockholders Equity	5.71B	5.78B	3.34B	3.02B	2.22B
Cash Flow
Free Cash Flow	0.00	28.05M	260.88M	-99.57M	559.44M
Operating Cash Flow	0.00	915.55M	823.68M	461.15M	762.98M
Investing Cash Flow	0.00	-1.09B	-577.35M	-575.46M	82.78M
Financing Cash Flow	0.00	1.38B	-1.35M	-172.21M	-360.17M

Kohjin Bio Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1525.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Negative. The current price of 1525 is above the 20-day moving average (MA) of 1479.65, above the 50-day MA of 1516.66, and below the 200-day MA of 1632.08, indicating a bearish trend. The MACD of -27.01 indicates Positive momentum. The RSI at 28.98 is Positive, neither overbought nor oversold. The STOCH value of 22.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:177A.

Kohjin Bio Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥16.95B	53.11	―	―	12.91%	37.96%
177A	67 Neutral	¥7.28B	10.12	―	1.62%	―	―
2342	56 Neutral	¥4.96B	-5.58	―	―	-0.77%	-288.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4588	50 Neutral	¥44.44B	-18.47	―	―	-9.04%	13.09%
4591	43 Neutral	¥4.56B	-3.54	―	―	-100.00%	7.60%
4594	39 Underperform	¥5.99B	-4.59	―	―	1221.43%	30.54%